Evidence Hub

Pediatric Patients Have Shorter Lansoprazole Half-Life Than Previously Reported

Jeffrey Phillips, Jane E. Burnett, Shan H. Siddiqi, Marcella Bothwell

The American Journal of Gastroenterology, 2007

Abstract

Purpose: Traditional pharmacokinetic teaching suggests that the elimination rate (half-life) of drugs is related to patient age. However, the package insert for lansoprazole, a common proton-pump inhibitor (PPI) drug, reports that its “pharmacokinetics in pediatric patients aged 1 to 17 years [are] similar to those observed in healthy adult subjects.” Numerous recent articles, in contrast, suggest that higher dosages are needed for children, although these articles establish no definite pharmacokinetic relationship between patient age and drug half-life. Establishing the correct half-life is important for appropriate dosage regimen development for PPI drugs. Methods: Evaluation of previously published literature reveals an unusually large degree of variability in most studies. This variation can be caused by: (1) rapid versus slow metabolizer status based on genetic variation in Cytochrome P450, (2) immature hepatic function, (3) hepatic dysfunction, and (4) errors related to timing of blood draws with enteric-coated products. Meanwhile, when the ages of the patients in the same studies are plotted against the respective half-lives of lansoprazole, an increase in half-life with age is observable. After removing data involving patients with immature hepatic function and eliminating outlying points by using statistically acceptable methods, the relationship between age and half-life becomes even more evident.TableTo further investigate this relationship between age and…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free